
Surgery Partners (SGRY) Stock Forecast & Price Target
Surgery Partners (SGRY) Analyst Ratings
Bulls say
Surgery Partners is well positioned to continue generating strong growth, with a diverse portfolio of ambulatory surgical centers and short-stay hospitals. The recent divestiture of its Idaho Falls market will have a positive impact on revenue, EBITDA, and balance sheet leverage, allowing the company to focus on its high-efficiency facilities and expand its capabilities in targeted high-acuity specialties. The company's strategic investments, de novo pipeline, and disciplined M&A strategy support a multi-year growth story, leading to sustainable, double-digit EBITDA growth and long-term value creation for shareholders.
Bears say
Surgery Partners is heavily dependent on managed care and Medicare payment rates, which are subject to change and could negatively impact the company's financial performance. There is also a risk of integration challenges as the company continues to acquire new assets. Additionally, labor cost inflation and revenue concentration pose potential threats to the company's profitability. Despite recent divestitures, Surgery Partners remains highly leveraged and may face difficulties in managing its debt load. Overall, these factors make the stock unattractive for investment, with a low likelihood of significant price appreciation.
This aggregate rating is based on analysts' research of Surgery Partners and is not a guaranteed prediction by Public.com or investment advice.
Surgery Partners (SGRY) Analyst Forecast & Price Prediction
Start investing in Surgery Partners (SGRY)
Order type
Buy in
Order amount
Est. shares
0 shares